Clinical Trials Directory

Trials / Completed

CompletedNCT02597543

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Paul Kim · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal graft function. The investigators hypothesize that patients with nonspecific allograft dysfunction will demonstrate decreased myocardial perfusion reserve, related to microvascular allograft vasculopathy, compared to those with normal graft function.

Detailed description

Adult heart-transplant patients, excluding those with a GFR less than 30 mL/min/1.73m2, contraindications to MRI and allergies to either regadenoson or gadolinium contrast, will be enrolled over 10 months. Patients will be recruited from UC San Diego and San Diego Veterans Affairs. The investigators will specifically enroll patients with nonspecific allograft dysfunction and patients with normal graft function. Brief protocol: Cardiac MRI is performed. Cine images in standard views are obtained. T2 mapping sequences are performed on short axis images. For stress imaging, intravenous regadenoson is given as a 0.4 mg bolus followed by a 5 mL saline flush. After 30 seconds, short-axis images are acquired for 30 consecutive heartbeats with administration of gadolinium. Rest imaging is performed 30 minutes after stress imaging. Lastly, late gadolinium enhancement images are obtained in standard views. Images are analyzed offline by a blinded independent reader. Patients will be followed for one month after enrollment for MACE.

Conditions

Interventions

TypeNameDescription
DRUGRegadenosonFor use in stress myocardial perfusion imaging.
DRUGGadoliniumFor use in both perfusion imaging and late gadolinium enhancement.
PROCEDURECardiac MRICardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.

Timeline

Start date
2015-11-01
Primary completion
2016-06-30
Completion
2016-06-30
First posted
2015-11-05
Last updated
2017-08-22
Results posted
2017-08-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02597543. Inclusion in this directory is not an endorsement.